ReviewCurrent pharmaceutical design2025

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment.

Navneet Sharma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.